Samuel L Cytryn, Neeta Pandit-Taskar, Melissa A Lumish, Steven B Maron, Ping Gu, Geoffrey Y Ku, Joanne F Chou, Marinela Capanu, Ariel Antoine, Diane Loegel, Lara Feder, Steven Philemond, Serge K Lyashchenko, Jason S Lewis, Viktoriya Paroder, Amitabh Srivastava, Laura H Tang, Heiko Schoder, Yelena Y Janjigian
Anti-programmed death 1 (PD-1) inhibitors are the standard of care for advanced gastroesophageal cancer. Although recommendations and approval by regulatory agencies are often based on programmed death ligand 1 (PD-L1) expression, pathologic assessments of PD-L1 status have several limitations. Single-site biopsies do not adequately capture disease heterogeneity within individual tumor lesions or among several lesions within the same patient, the PD-L1 combined positive score is a dynamic biomarker subject to evolution throughout a patient's disease course, and repeated biopsies are invasive and not always feasible...
March 21, 2024: Journal of Nuclear Medicine